{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:41:25Z","timestamp":1791848485197,"version":"4.3.4"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01 NS125778"],"award-info":[{"award-number":["R01 NS125778"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015691","name":"National Institute of Allergy and Infectious Diseases Division of Microbiology and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI176670"],"award-info":[{"award-number":["R01AI176670"]}],"id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015691","name":"National Institute of Allergy and Infectious Diseases Division of Microbiology and Infectious Diseases","doi-asserted-by":"publisher","award":["T35AI078878"],"award-info":[{"award-number":["T35AI078878"]}],"id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.vaccine.2026.128255","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T04:15:21Z","timestamp":1769055321000},"page":"128255","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["VSA-2-, a novel plant-derived adjuvant for SARS-CoV-2 subunit vaccine"],"prefix":"10.1016","volume":"75","author":[{"given":"Awadalkareem","family":"Adam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christy","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madison C.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brinley R.","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bi-Hung","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuping","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128255_bb0005","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.vaccine.2014.10.078","article-title":"Vaccine adjuvant systems containing monophosphoryl lipid A and QS-21 induce strong humoral and cellular immune responses against hepatitis B surface antigen which persist for at least 4 years after vaccination","volume":"33","author":"Leroux-Roels","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128255_bb0010","doi-asserted-by":"crossref","first-page":"4203","DOI":"10.1016\/j.vaccine.2007.03.012","article-title":"Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naive adults at the Walter Reed Army Institute of Research","volume":"25","author":"Polhemus","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128255_bb0015","doi-asserted-by":"crossref","first-page":"6483","DOI":"10.1016\/j.vaccine.2006.06.033","article-title":"Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S\/AS02A","volume":"24","author":"Stewart","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128255_bb0020","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.vaccine.2010.12.009","article-title":"Immunogenicity and safety of an investigational AS02(v)-adjuvanted hepatitis B vaccine in patients with renal insufficiency who failed to respond or to maintain antibody levels after prior vaccination: results of two open, randomized, comparative trials","volume":"29","author":"Tielemans","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128255_bb0025","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.vaccine.2007.12.038","article-title":"Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers","volume":"26","author":"Vandepapeliere","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128255_bb0030","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1016\/j.vaccine.2004.11.034","article-title":"Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults","volume":"23","author":"Vandepapeliere","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128255_bb0035","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/978-1-4419-1603-7_10","article-title":"Monophosphoryl lipid a (MPL) as an adjuvant for anti-cancer vaccines: clinical results","volume":"667","author":"Cluff","year":"2010","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.vaccine.2026.128255_bb0040","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1016\/j.vaccine.2005.03.042","article-title":"An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model","volume":"23","author":"Robert Putnak","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128255_bb0045","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1080\/14760584.2024.2382725","article-title":"Adjuvant system AS01: from mode of action to effective vaccines","volume":"23","author":"Roman","year":"2024","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2026.128255_bb0050","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1126\/science.adg8823","article-title":"A booster for vaccines from plants","volume":"379","author":"Chubatsu Nunes","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2026.128255_bb0055","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/BF02866642","article-title":"Industrial uses and sustainable supply of Quillaja Saponaria (Rosaceae) saponins","volume":"53","author":"Martin","year":"1999","journal-title":"Econ Bot"},{"key":"10.1016\/j.vaccine.2026.128255_bb0060","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1586\/erv.11.18","article-title":"Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer","volume":"10","author":"Ragupathi","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2026.128255_bb0065","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.biopha.2018.06.026","article-title":"Efficacy and safety of immunological adjuvants. Where is the cut-off?","volume":"105","author":"Batista-Duharte","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.vaccine.2026.128255_bb0070","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1021\/acs.jmedchem.9b02063","article-title":"Structural effect on adjuvanticity of saponins","volume":"63","author":"Wang","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.vaccine.2026.128255_bb0075","doi-asserted-by":"crossref","first-page":"9976","DOI":"10.1021\/acs.jmedchem.9b01511","article-title":"Vaccine adjuvants derivatized from Momordica saponins I and II","volume":"62","author":"Wang","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.vaccine.2026.128255_bb0080","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1007\/s00044-024-03227-x","article-title":"Development of semisynthetic saponin immunostimulants","volume":"33","author":"Bai","year":"2024","journal-title":"Med Chem Res"},{"key":"10.1016\/j.vaccine.2026.128255_bb0085","first-page":"10","article-title":"Adjuvant effects of a new saponin Analog VSA-1 on enhancing homologous and heterosubtypic protection by influenza virus vaccination","author":"Bhatnagar","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2026.128255_bb0090","doi-asserted-by":"crossref","first-page":"1079047","DOI":"10.3389\/fimmu.2022.1079047","article-title":"Potentiating pneumococcal glycoconjugate vaccine PCV13 with saponin adjuvant VSA-1","volume":"13","author":"Kim","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2026.128255_bb0095","doi-asserted-by":"crossref","first-page":"14589","DOI":"10.1021\/acs.jmedchem.2c01087","article-title":"Structure-activity relationship study of Momordica saponin II derivatives as vaccine adjuvants","volume":"65","author":"Kim","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.vaccine.2026.128255_bb0100","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41579-020-00468-6","article-title":"Coronavirus biology and replication: implications for SARS-CoV-2","volume":"19","author":"V\u2019Kovski","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2026.128255_bb0105","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.chom.2020.02.001","article-title":"Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China","volume":"27","author":"Wu","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.vaccine.2026.128255_bb0110","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41392-021-00523-5","article-title":"SARS-CoV-2 spike protein: a key target for eliciting persistent neutralizing antibodies","volume":"6","author":"Yang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.vaccine.2026.128255_bb0115","doi-asserted-by":"crossref","first-page":"5490","DOI":"10.4049\/jimmunol.181.8.5490","article-title":"T cell responses to whole SARS coronavirus in humans","volume":"181","author":"Li","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2026.128255_bb0120","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41577-020-00480-0","article-title":"Viral targets for vaccines against COVID-19","volume":"21","author":"Dai","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2026.128255_bb0125","series-title":"FDA approves Novavax's Nuvaxovid 2025-2026 formula COVID-19 vaccine","author":"Levy","year":"2025"},{"key":"10.1016\/j.vaccine.2026.128255_bb0130","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.936523","article-title":"Editorial: first approval of the protein-based adjuvanted Nuvaxovid (NVX-CoV2373) Novavax vaccine for SARS-CoV-2 could increase vaccine uptake and provide immune protection from viral variants","volume":"28","author":"Parums","year":"2022","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.vaccine.2026.128255_bb0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003769","article-title":"Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: a phase 2 randomized placebo-controlled trial","volume":"18","author":"Formica","year":"2021","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2026.128255_bb0140","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/978-1-59745-402-5_7","article-title":"Analysis of Th1\/Th2 T-cell subsets","volume":"136","author":"Skapenko","year":"2007","journal-title":"Methods Mol Med"},{"key":"10.1016\/j.vaccine.2026.128255_bb0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3001284","article-title":"Mouse-adapted SARS-CoV-2 protects animals from lethal SARS-CoV challenge","volume":"19","author":"Muruato","year":"2021","journal-title":"PLoS Biol"},{"issue":"119\u201327","key":"10.1016\/j.vaccine.2026.128255_bb0150","article-title":"Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19","volume":"146","author":"Yang","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2026.128255_bb0155","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/s41577-020-0331-4","article-title":"Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages","volume":"20","author":"Merad","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2026.128255_bb0160","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1126\/science.abb8923","article-title":"Rapid COVID-19 vaccine development","volume":"368","author":"Graham","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2026.128255_bb0165","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.virol.2021.11.011","article-title":"A two-dose optimum for recombinant S1 protein-based COVID-19 vaccination","volume":"566","author":"Hu","year":"2022","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2026.128255_bb0170","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abj1476","article-title":"Lyophilized, thermostable spike or RBD immunogenic liposomes induce protective immunity against SARS-CoV-2 in mice","volume":"7","author":"Mabrouk","year":"2021","journal-title":"Sci Adv"},{"key":"10.1016\/j.vaccine.2026.128255_bb0175","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s41541-023-00759-y","article-title":"Human in vitro modeling of adjuvant formulations demonstrates enhancement of immune responses to SARS-CoV-2 antigen","volume":"8","author":"Doss-Gollin","year":"2023","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2026.128255_bb0180","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1093\/infdis\/jiad260","article-title":"T-cell immunity against severe acute respiratory syndrome coronavirus 2 measured by an interferon-gamma release assay is strongly associated with patient outcomes in vaccinated persons hospitalized with Delta or omicron variants","volume":"228","author":"Fernandez-Gonzalez","year":"2023","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128255_bb0185","doi-asserted-by":"crossref","first-page":"26660","DOI":"10.1038\/s41598-024-77969-4","article-title":"IFN-gamma derived from activated human CD4(+) T cells inhibits the replication of SARS-CoV-2 depending on cell-type and viral strain","volume":"14","author":"Shimizu","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2026.128255_bb0190","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/nchem.1963","article-title":"Development of a minimal saponin vaccine adjuvant based on QS-21","volume":"6","author":"Fernandez-Tejada","year":"2014","journal-title":"Nat Chem"},{"key":"10.1016\/j.vaccine.2026.128255_bb0195","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1006\/viro.1998.9060","article-title":"Stimulation of local immunity and protection in mice by intramuscular immunization with triple- or double-layered rotavirus particles and QS-21","volume":"243","author":"McNeal","year":"1998","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2026.128255_bb0200","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/0264-410X(94)90036-1","article-title":"Impact of the saponin adjuvant QS-21 and aluminium hydroxide on the immunogenicity of recombinant OspA and OspB of Borrelia burgdorferi","volume":"12","author":"Ma","year":"1994","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128255_bb0205","doi-asserted-by":"crossref","first-page":"29368","DOI":"10.1038\/srep29368","article-title":"Potent response of QS-21 as a vaccine adjuvant in the skin when delivered with the Nanopatch, resulted in adjuvant dose sparing","volume":"6","author":"Ng","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2026.128255_bb0210","first-page":"10","article-title":"A SARS-CoV-2 Spike Ferritin Nanoparticle Vaccine Is Protective and Promotes a Strong Immunological Response in the Cynomolgus Macaque Coronavirus Disease 2019 (COVID-19) Model","author":"Johnston","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2026.128255_bb0215","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1016\/j.vaccine.2012.01.088","article-title":"Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice","volume":"30","author":"Dendouga","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128255_bb0220","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2106433118","article-title":"Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques","volume":"118","author":"King","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2026.128255_bb0225","article-title":"SARS-CoV-2 RBD neutralizing antibody induction is enhanced by particulate vaccination","volume":"32","author":"Huang","year":"2020","journal-title":"Adv Mater"},{"key":"10.1016\/j.vaccine.2026.128255_bb0230","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41577-021-00526-x","article-title":"COVID-19 vaccines: modes of immune activation and future challenges","volume":"21","author":"Teijaro","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2026.128255_bb0235","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/nri1439","article-title":"NALT- versus Peyer\u2019s-patch-mediated mucosal immunity","volume":"4","author":"Kiyono","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2026.128255_bb0240","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.trsl.2022.06.004","article-title":"A modified porous silicon microparticle potentiates protective systemic and mucosal immunity for SARS-CoV-2 subunit vaccine","volume":"249","author":"Adam","year":"2022","journal-title":"Transl Res"},{"key":"10.1016\/j.vaccine.2026.128255_bb0245","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1248\/cpb.33.464","article-title":"Studies on the constituents of Momordica cochinchinensis SPRENG. I. Isolation and characterization of the seed saponins, momordica saponins I and II","volume":"33","author":"Iwamoto","year":"1985","journal-title":"Chem Pharm Bull"},{"key":"10.1016\/j.vaccine.2026.128255_bb0250","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1002\/anie.201509398","volume":"55","author":"Solleder","year":"2016","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.vaccine.2026.128255_bb0255","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1021\/op800240d","article-title":"A practical method for functionalized peptide or amide bond formation in aqueous-ethanol media with EDC as activator","volume":"13","author":"Pu","year":"2009","journal-title":"Org Process Res Dev"},{"key":"10.1016\/j.vaccine.2026.128255_bb0260","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41541-023-00753-4","article-title":"A single-dose of intranasal vaccination with a live-attenuated SARS-CoV-2 vaccine candidate promotes protective mucosal and systemic immunity","volume":"8","author":"Adam","year":"2023","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2026.128255_bb0265","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/s41467-022-28544-w","article-title":"Neutralization against omicron SARS-CoV-2 from previous non-omicron infection","volume":"13","author":"Zou","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2026.128255_bb0270","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1574-695X.2011.00840.x","article-title":"Vgamma4+ T cells regulate host immune response to West Nile virus infection","volume":"63","author":"Welte","year":"2011","journal-title":"FEMS Immunol Med Microbiol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26000629?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26000629?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T03:55:39Z","timestamp":1782014139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26000629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":54,"alternative-id":["S0264410X26000629"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128255","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.09.22.677856","asserted-by":"object"}]},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"VSA-2-, a novel plant-derived adjuvant for SARS-CoV-2 subunit vaccine","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128255","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128255"}}